



PTO/SB/21 (01-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/047,749	
	Filing Date	October 23, 2001	
	First Named Inventor	Lehmann, Paul	
	Art Unit	1647	
	Examiner Name	Nichols, Christopher	
Total Number of Pages in This Submission	8	Attorney Docket Number	20356 US1

RECEIVED
SEP 03 2003
TECH CENTER 1600/2400

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input checked="" type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Patricia S. Rocha-Tramaloni
Signature	
Date	August 27, 2003

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date <u>August 27, 2003</u>	
Typed or printed	Patricia S. Rocha-Tramaloni
Signature	
Date	August 27, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Corres. and Mail
BOX AF

PATENT APPLICATION

RECEIVED

SEP 03 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor: Paul Lehmann

Group: 1647 ✓

Serial No. 10/047,749, filed October 23, 2001
(Ref. No. 20356 US1)

Examiner: Nichols, Christopher J

For: **METHOD FOR TREATING DISTURBANCES IN IRON METABOLISM USING A
COMBINATION OF ERYTHROPOIETIN AND IRON**

COMMUNICATION AFTER FINAL REJECTION
UNDER 37 CFR § 1.116

RESPONSE UNDER 37 CFR 1.116

EXPEDITED PROCEDURE

EXAMINING GROUP

1647

Nutley, New Jersey 07110
August 27, 2003

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This communication is responsive to the final office action dated July 2, 2003, a response to which is due on or before October 2, 2003. Entry of this communication is respectfully requested to place the application in condition for allowance.

Submitted herewith is a terminal disclaimer over commonly owned US Pat. No. 6,372,715 B1.

Discussion

The claims pending in this application are claims 15, 16 and 19-29. All prior objections to the specification and rejections of the claims are withdrawn.

No new subject matter is presented by this communication.


Pending claims 15, 16 and 19-27 are newly rejected under the judicially created doctrine of obvious-type non-statutory double patenting as being unpatentable over US Pat. No. 6,372,715 B1 in view of Mercuriali and Inghilleri., "Iron administration to optimize the effect of r-HuEPO in the surgical setting," Erythropoiesis: New Dimension in the Treatment of Anemia, 6:67-76 (1995), taken together with Pincus *et al.*, "Multicultural Study of Recombinant Numan Erythropoietin in Correction of Anemia in Rheumatoid Arthritis," The American Journal of Medicine 89(2):161-168. Applicants submit herewith a terminal disclaimer over the '715 patent. This rejection is thus overcome.

Serial No. 10/047,749
Filed: October 23, 2001

Conclusion

In view of the foregoing comments and the submission of the terminal disclaimer, this application is now in condition for allowance and applicants solicit early action to that end.

Respectfully submitted,



Attorney for applicant(s)
Patricia S. Rocha-Tramaloni
(Reg. No. 31,054)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-2441
Telefax: (973) 235-2363

133664